Nano Dimension Ltd. (NASDAQ:NNDM) recently provided shareholders with an update on its planned business integration with Infinite Epigenetics. This announcement, made on June 16, 2026, elaborated on the ongoing negotiations and addressed concerns raised by Murchison regarding the transaction.

Nano Dimension emphasized that Infinite Epigenetics is a robust entity, not merely a conceptual venture or an AI shell company. It highlights Infinite's active businesses, a CLIA-certified methylation laboratory, existing revenue streams, a network of over 7,500 healthcare professionals, patented intellectual property, and a proprietary database containing more than 120,000 biological samples. The company also noted Infinite's team has contributed to over 50 publications, and their CLIA-certified lab can process more than one million epigenetic signals from a single sample. This strategic move, chosen from approximately 20 evaluated opportunities, signifies Nano Dimension's shift from 3D printing to AI-driven preventive health and diagnostic solutions.

The proposed merger, which involved an extensive review process with financial, legal, and technological advisors, values Nano Dimension at its net cash plus a 20% premium. It is designed to maintain Nano's Nasdaq listing, preserve the value of its legacy assets through contingent value rights, and offer additional equity upside. Nano Dimension clarified that the transaction does not include separate or deal-specific compensation or payouts, and any definitive agreement will require shareholder approval.

This transformative merger highlights the dynamic nature of technology and investment, where companies adapt and evolve to seize new opportunities. By transitioning into AI-powered health and diagnostics, Nano Dimension is positioning itself at the forefront of innovation, aiming to create long-term value for its stakeholders and contribute to advancements in medical technology.